company background image
KYMR

Kymera Therapeutics NasdaqGM:KYMR Stock Report

Last Price

US$34.29

Market Cap

US$2.0b

7D

-6.3%

1Y

-20.6%

Updated

08 Feb, 2023

Data

Company Financials +

Kymera Therapeutics, Inc.

NasdaqGM:KYMR Stock Report

Mkt Cap: US$2.0b

KYMR Stock Overview

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system.

KYMR fundamental analysis
Snowflake Score
Valuation0/6
Future Growth2/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

Kymera Therapeutics, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Kymera Therapeutics
Historical stock prices
Current Share PriceUS$34.29
52 Week HighUS$46.22
52 Week LowUS$13.15
Beta1.71
1 Month Change26.86%
3 Month Change12.02%
1 Year Change-20.59%
3 Year Changen/a
5 Year Changen/a
Change since IPO3.10%

Recent News & Updates

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Recent updates

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Dec 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Are In A Position To Invest In Growth

Kymera KT-333 gets FDA orphan drug status for blood cancer subtype

Sep 15

Kymera initiated at buy at Jefferies on promise in oncology, autoimmune spaces

Aug 15

Kymera Therapeutics GAAP EPS of -$0.78 misses by $0.08, revenue of $11.51M misses by $3.46M

Aug 09

Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Jul 04
Here's Why We're Not Too Worried About Kymera Therapeutics' (NASDAQ:KYMR) Cash Burn Situation

Kymera Therapeutics: A First Take

Feb 28

Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth

Feb 28
Companies Like Kymera Therapeutics (NASDAQ:KYMR) Can Afford To Invest In Growth

Kymera's Protein Degrader Platform Tech Moves Forward With 3rd Candidate; Updated Data On KT-474 In December At R&D Day

Nov 30

Kymera: Targeting The Protein Degradation Space

Oct 22

Analysts Just Shaved Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Forecasts Dramatically

Aug 08
Analysts Just Shaved Their Kymera Therapeutics, Inc. (NASDAQ:KYMR) Forecasts Dramatically

Kymera Therapeutics names Elaine Caughey as chief business officer

Jun 21

Kymera Therapeutics presents new data demonstrating proof-of-degradation using E3 ligase

May 26

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are More Bearish Than They Used To Be

May 11
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are More Bearish Than They Used To Be

Kymera posts positive preclinical data on IRAK4 degrader KT-474

May 10

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

May 08
Kymera Therapeutics, Inc. (NASDAQ:KYMR) Analysts Are Cutting Their Estimates: Here's What You Need To Know

Kymera Therapeutics EPS misses by $0.14, misses on revenue

May 06

Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like

Mar 06
Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like

Kymera Therapeutics Is A Protein Degrading Pioneer With A Triple-Figure Share Price In Waiting

Jan 14

Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like

Nov 21
Here's What Kymera Therapeutics, Inc.'s (NASDAQ:KYMR) Shareholder Ownership Structure Looks Like

Kymera's protein degradation programs show encouraging preclinical action in cancer

Nov 04

Shareholder Returns

KYMRUS BiotechsUS Market
7D-6.3%-0.5%1.6%
1Y-20.6%2.9%-10.8%

Return vs Industry: KYMR underperformed the US Biotechs industry which returned 2.9% over the past year.

Return vs Market: KYMR underperformed the US Market which returned -10.8% over the past year.

Price Volatility

Is KYMR's price volatile compared to industry and market?
KYMR volatility
KYMR Average Weekly Movement11.4%
Biotechs Industry Average Movement12.0%
Market Average Movement6.7%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market2.8%

Stable Share Price: KYMR is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 11% a week.

Volatility Over Time: KYMR's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2015169Nello Mainolfihttps://www.kymeratx.com

Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program, which is in Phase I clinical trial for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, macrophage activation syndrome, general pustular psoriasis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases and fibrosis; and MDM2 program to treat hematological malignancies and solid tumors. The company was incorporated in 2015 and is headquartered in Watertown, Massachusetts.

Kymera Therapeutics, Inc. Fundamentals Summary

How do Kymera Therapeutics's earnings and revenue compare to its market cap?
KYMR fundamental statistics
Market CapUS$2.04b
Earnings (TTM)-US$153.84m
Revenue (TTM)US$45.96m

40.7x

P/S Ratio

-12.2x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
KYMR income statement (TTM)
RevenueUS$45.96m
Cost of RevenueUS$158.64m
Gross Profit-US$112.68m
Other ExpensesUS$41.16m
Earnings-US$153.84m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

Feb 23, 2023

Earnings per share (EPS)-2.82
Gross Margin-245.16%
Net Profit Margin-334.72%
Debt/Equity Ratio0%

How did KYMR perform over the long term?

See historical performance and comparison